SCHEMBL19024413

SCHEMBL19024413

COc1cc2c(cc1OC)[C@H]1C[C@@H](OC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H](CC(C)C)CN1CC2

nearest known ligand 0.70

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 1/20 0.70
▸ TBXA2R P21731 1/20 0.70
▸ PTGS1 P23219 1/20 0.70
▸ OPRM1 P35372 1/20 0.70
▸ KCNH2 Q12809 1/20 0.70
▸ SLC18A2 Q05940 10/20 0.59
▸ HTR2A P28223 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22612168 1.00 HTR1A (0.70) HTR1ATBXA2RPTGS1OPRM1KCNH2
SCHEMBL19024411 1.00 HTR1A (0.70) HTR1ATBXA2RPTGS1OPRM1KCNH2
SCHEMBL22612151 1.00 HTR1A (0.70) HTR1ATBXA2RPTGS1OPRM1KCNH2
SCHEMBL20049853 1.00 HTR1A (0.70) HTR1ATBXA2RPTGS1OPRM1KCNH2
SCHEMBL19024412 1.00 HTR1A (0.70) HTR1ATBXA2RPTGS1OPRM1KCNH2
SCHEMBL22612169 1.00 HTR1A (0.70) HTR1ATBXA2RPTGS1OPRM1KCNH2
SCHEMBL24520555 0.94 HTR1A (0.63) HTR1ATBXA2RPTGS1OPRM1KCNH2
SCHEMBL22579550 0.93 HTR1A (0.65) HTR1ATBXA2RPTGS1OPRM1KCNH2
SCHEMBL20049817 0.87 HTR1A (0.77) HTR1ATBXA2RPTGS1OPRM1KCNH2
SCHEMBL21706281 0.87 HTR1A (0.77) HTR1ATBXA2RPTGS1OPRM1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3394057-B1 SYNTHETIC METHOD FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]LSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) NEUROCRINE BIOSCIENCES INC (US) 2022-03-30 — — EP claimed
US-10160757-B2 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Neuroscrine Biosciences, Inc. (US) 2018-12-25 — — US claimed
US-20170183346-A1 SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11bR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11b-HEXAHYDRO-1H-PYRIDO[2,1-a]ISOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) AGNO PHARMA USA 2017-06-29 — — US claimed
US-20240239791-A1 PROCESSES FOR THE SYNTHESIS OF VALBENAZINE NEUROCRINE BIOSCIENCES, INC. 2024-07-18 — — US disclosed
US-20240239791-A1 PROCESSES FOR THE SYNTHESIS OF VALBENAZINE NEUROCRINE BIOSCIENCES, INC. 2024-07-18 — — US disclosed
US-20240239791-A1 PROCESSES FOR THE SYNTHESIS OF VALBENAZINE NEUROCRINE BIOSCIENCES, INC. 2024-07-18 — — US disclosed
CN-117480170-A Method for synthesizing valphenazine 纽罗克里生物科学有限公司 2024-01-30 — — CN disclosed
WO-2022232060-A1 PROCESSES FOR THE SYNTHESIS OF VALBENAZINE NEUROCRINE BIOSCIENCES, INC. (US) 2022-11-03 — — WO disclosed
EP-3394057-B1 SYNTHETIC METHOD FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]LSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) NEUROCRINE BIOSCIENCES INC (US) 2022-03-30 — — EP disclosed
EP-3394057-B1 SYNTHETIC METHOD FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]LSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) NEUROCRINE BIOSCIENCES INC (US) 2022-03-30 — — EP disclosed
US-11242341-B2 Solid state forms of valbenazine ASSIA CHEMICAL INDUSTRIES LTD. (IL) 2022-02-08 — — US disclosed
US-20200347057-A1 SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) AGNO PHARMA USA 2020-11-05 — — US disclosed
WO-2020213014-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF VALBENAZINE AND ITS SALTS MYLAN LABORATORIES LIMITED (IN) 2020-10-22 — — WO disclosed
US-20200181140-A1 SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11bR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11b-HEXAHYDRO-1H-PYRIDO[2,1-a]ISOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) NEUROCRINE BIOSCIENCES, INC. 2020-06-11 — — US disclosed
US-20200181140-A1 SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11bR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11b-HEXAHYDRO-1H-PYRIDO[2,1-a]ISOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) NEUROCRINE BIOSCIENCES, INC. 2020-06-11 — — US disclosed
US-20200048244-A1 SOLID STATE FORMS OF VALBENAZINE ASSIA CHEM IND LTD (IL) 2020-02-13 — — US disclosed
US-10160757-B2 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) Neuroscrine Biosciences, Inc. (US) 2018-12-25 — — US disclosed
WO-2017112857-A1 SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) NEUROCRINE BIOSCIENCES, INC. (US) 2017-06-29 — — WO disclosed
US-20170183346-A1 SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11bR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11b-HEXAHYDRO-1H-PYRIDO[2,1-a]ISOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) AGNO PHARMA USA 2017-06-29 — — US disclosed
US-20170183346-A1 SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11bR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11b-HEXAHYDRO-1H-PYRIDO[2,1-a]ISOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) AGNO PHARMA USA 2017-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048244-A1 SOLID STATE FORMS OF VALBENAZINE VARS1, CYP3A5, CYP3A4 HTR1A 2678/4885TBXA2R 3224/4885PTGS1 2866/4885
US-20170183346-A1 SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11bR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11b-HEXAHYDRO-1H-PYRIDO[2,1-a]ISOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) CYP2S1, CYP26B1, CYP4B1 HTR1A 158/4885TBXA2R 1082/4885PTGS1 2269/4885
US-20240239791-A1 PROCESSES FOR THE SYNTHESIS OF VALBENAZINE SLC18A2, SLC18A3, SLC6A3 HTR1A 237/4885TBXA2R 2254/4885PTGS1 4420/4885
US-10160757-B2 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) CYP2S1, CYP26B1, CYP4B1 HTR1A 158/4885TBXA2R 1082/4885PTGS1 2269/4885
US-11242341-B2 Solid state forms of valbenazine VARS1, CYP3A5, CYP3A4 HTR1A 2678/4885TBXA2R 3224/4885PTGS1 2866/4885
US-20200347057-A1 SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) CYP2S1, CYP26B1, UGT2B7 HTR1A 202/4885TBXA2R 781/4885PTGS1 2439/4885
US-20200181140-A1 SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11bR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11b-HEXAHYDRO-1H-PYRIDO[2,1-a]ISOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) CYP2S1, CYP26B1, CYP4B1 HTR1A 148/4885TBXA2R 1018/4885PTGS1 2493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback